KRAS-ERK switch could revive chemotherapy response in pancreatic cancer
Researchers identify a KRAS/ERK/JUNB signaling axis that suppresses the differentiation regulator GATA6, pushing pancreatic tumors from a classical, chemo‑sensitive state to a basal, chemo‑resistant one; inhibiting this pathway raises GATA6 levels, reverting cells to a more treatable state and enhancing the effectiveness of standard chemotherapy when paired with targeted therapies.